Nektar Therapeutics Finalizes $400M Public Offering at Premium to Fund Phase 3 Trials

summarizeSummary

Nektar Therapeutics finalized a public offering of common stock and pre-funded warrants, raising approximately $375.6 million at a significant premium to its prior trading price, to fund critical Phase 3 clinical trials for rezpegaldesleukin.

check_boxKey Events

• Offering Finalized

  Nektar Therapeutics finalized its public offering of 6,603,449 shares of common stock and pre-funded warrants to purchase up to 293,103 shares of common stock.

• Significant Capital Raise

  The offering is expected to generate approximately $375.6 million in net proceeds for the company, before expenses.

• Premium Pricing Achieved

  Shares were offered at $58.00, a substantial premium to the $37.07 closing price on February 9, 2026, demonstrating strong institutional demand following recent positive clinical data.

• Funding for Phase 3 Trials

  Proceeds will primarily fund research and development, clinical development (including Phase 3 trials for rezpegaldesleukin), and manufacturing costs.

auto_awesomeAnalysis

This 424B5 filing finalizes the terms and pricing of the public offering previously initiated on February 10, 2026. Nektar Therapeutics successfully raised approximately $375.6 million through the sale of common stock and pre-funded warrants. The offering was priced at $58.00 per share, representing a significant premium over the $37.07 closing price on February 9, 2026, just prior to the announcement of positive clinical trial results for rezpegaldesleukin. This premium pricing indicates strong institutional demand and confidence, likely driven by the positive 36-week maintenance results for rezpegaldesleukin in atopic dermatitis, which were announced concurrently with the preliminary offering details. While the offering is dilutive, the substantial capital infusion is crucial for Nektar Therapeutics to advance its drug candidates, particularly the planned Phase 3 trials for rezpegaldesleukin, extending its operational runway and supporting long-term development goals. The ability to raise capital at such a premium is a strong positive signal for the company's financial health and strategic execution.